Strohbehn GW, Holleman R, Burns J, Klamerus ML, et al. Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation. JAMA Oncol 2022;8:1663-1667.
PMID: 36136314